Pipeline

Project Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Regulatory Approval
Motixafortide (BL-8040) HSC Mobilization in Multiple Myeloma (NDA Submitted to FDA)
Pancreatic Cancer 1L
Pancreatic Cancer 1L (Investigator Initiated Study, In Combination with Libtayo)
HSC Mobilization in Sickle Cell Disease (Investigator Initiated Study)
AGI-134 Solid tumors

Motixafortide (BL-8040)

Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4, is ...

INDICATIONS : 2

CLINICAL STUDIES : 13

AGI-134

AGI-134 is a synthetic alpha-Gal glycolipid in development for solid tumors that is highly differentiated from other cancer ...

INDICATIONS : 1

CLINICAL STUDIES : 1